Browse by category

First US patient treated with Proximal Intestinal Mucosal Ablation for the treatment of T2DM

Aqua Medical has announced the successful treatment of the first US patient in its FDA authorised Investigational Device Exemption (IDE) clinical trial evaluating the company's proprietary Proximal Intestinal Mucosal Ablation (PIMA) procedure for the treatment of type 2 diabetes. Aqua Medical is investigating a new diabetes procedure called proximal intestinal mucosal ablation (Illustration courtesy of Aqua Medical) Aqua Medical's investigational PIMA procedure utilises the c

Framework focuses on the effects of excess adiposity on organs and tissues

Jul 31

First US patient treated with Proximal Intestinal Mucosal Ablation for the treatment of T2DM

Jul 28

Medtronic unveils Touch Surgery Aide - the next-generation compute platform for the OR

Jul 23

Browse by category

First US patient treated with Proximal Intestinal Mucosal Ablation for the treatment of T2DM

Browse by tag

Framework focuses on the effects of excess adiposity on organs and tissues

First US patient treated with Proximal Intestinal Mucosal Ablation for the treatment of T2DM

Medtronic unveils Touch Surgery Aide - the next-generation compute platform for the OR

Back to Top